Literature DB >> 17166771

Perimenopause and depression: strength of association, causal mechanisms and treatment recommendations.

M Elizabeth Gyllstrom1, Pamela J Schreiner, Bernard L Harlow.   

Abstract

Perimenopause represents a significant transition in a woman's life. The evidence to support an association between perimenopause and depression is mixed, yet recent prospective studies have provided stronger evidence to support such an association. Interpretation of study data are complicated by methodological issues, such as a lack of standard definition for perimenopause or depression, reducing comparability. A variety of causal factors, including psychological, genetic and physiological, have been implicated in depression during perimenopause, which lends weight to a multifactorial model. Physicians should consider initiating dialogue about menopause and symptom relief at age 40 and screening perimenopausal women for depressive symptoms. Selective serotonin reuptake inhibitors are a first line of treatment for depression, but hormone therapy could be considered for women experiencing menopausal symptoms unless there are contraindications. Future research should focus on establishing temporality and studying these potential relationships among women of different ethnicities.

Entities:  

Mesh:

Year:  2006        PMID: 17166771     DOI: 10.1016/j.bpobgyn.2006.11.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  7 in total

Review 1.  Menstrual cycle-related exacerbation of disease.

Authors:  Joann V Pinkerton; Christine J Guico-Pabia; Hugh S Taylor
Journal:  Am J Obstet Gynecol       Date:  2010-03       Impact factor: 8.661

2.  Influence of Stress and Depression on the Immune System in Patients Evaluated in an Anti-aging Unit.

Authors:  Beatriz Cañas-González; Alonso Fernández-Nistal; Juan M Ramírez; Vicente Martínez-Fernández
Journal:  Front Psychol       Date:  2020-08-04

3.  The role of cytokines and hot flashes in perimenopausal depression.

Authors:  Sokratis E Karaoulanis; Alexandros Daponte; Katerina A Rizouli; Andreas A Rizoulis; Georgios A Lialios; Catherine T Theodoridou; Christos Christakopoulos; Nikiforos V Angelopoulos
Journal:  Ann Gen Psychiatry       Date:  2012-04-10       Impact factor: 3.455

4.  Chaihu-Shugan-San administration ameliorates perimenopausal anxiety and depression in rats.

Authors:  Shujiao Chen; Tetsuya Asakawa; Shanshan Ding; Linghong Liao; Lingyuan Zhang; Jianying Shen; Jie Yu; Kenji Sugiyama; Hiroki Namba; Candong Li
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

5.  Effect of 17beta-estradiol on olfactory bulbectomy-induced oxidative stress and behavioral changes in rats.

Authors:  Inmaculada Tasset; José Peña; Ignacio Jimena; Montserrat Feijóo; María Del Carmen Muñoz; Pedro Montilla; Isaac Túnez
Journal:  Neuropsychiatr Dis Treat       Date:  2008-04       Impact factor: 2.570

6.  Reducing depression during the menopausal transition: study protocol for a randomised controlled trial.

Authors:  Osvaldo P Almeida; Kylie Marsh; Leon Flicker; Martha Hickey; Andrew Ford; Moira Sim
Journal:  Trials       Date:  2014-08-06       Impact factor: 2.279

7.  Hypericum Perforatum Decreased Hippocampus TNF-α and Corticosterone Levels with No Effect on Kynurenine/Tryptophan Ratio in Bilateral Ovariectomized Rats.

Authors:  Wesam M El-Bakly; Amany H Hasanin
Journal:  Korean J Physiol Pharmacol       Date:  2014-06-12       Impact factor: 2.016

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.